REGN - Spark Newswire

1 minute read

Cathie Wood’s ARK Invest Posts Fund Sales For Thursday, Aug. 12, 2021: OPEN, VEEV, SEER, RHHBY, REGN, PSTI, NVS, NTDOY, TWTR, DOCU, TER, SQ, SHOP, IOVA, SE, MCRB, XONE, GOOG, DDD, BYDDY, TTD, BABA

Today, 2:53 PM

Opendoor Technologies (OPEN) - 523,533 Shares Veeva Systems (VEEV) - 26,068 Seer (SEER) - 14,750 Roche (RHHBY) - 132,596 Regeneron Pharmaceuticals (REGN) - 42,669 Pluristem Therapeutics (PSTI) - 92,900 Novartis

BABA

1 minute read

Cathie Wood’s ARK Invest Posts Fund Sales For Wednesday, Aug. 11, 2021: TAK, SEER, REGN, PSTI, PSTG, NVS, TWTR, NTDOY, MCRB, DOCU, BIDU, NFLX, GRMN

By Michael Horton

Today, 2:53 PM

Takeda Pharmaceutical (TAK) - 189,804 Seer (SEER) - 7,800 Regeneron Pharmaceuticals (REGN) - 13,326 Pluristem Therapeutics (PSTI) - 45,155 Pure Storage (PSTG) - 131,501 Novartis (NVS) - 86,320 Twitter (TWTR) -

BIDU

1 minute read

Cathie Wood’s ARK Invest Posts Fund Sales For Tuesday, Aug. 10, 2021: SEER, TAK, RHHBY, REGN, PSTG, NVS, CLLS, BMY, TXG, SQ, SHOP, SE, NTDOY, MCRB, DOCU, NVDA, NFLX, BABA

By Michael Horton

Today, 2:53 PM

Seer (SEER) - 121,042 Shares Takeda Pharmaceutical (TAK) - 116,467 Roche (RHHBY) - 394,655 Regeneron Pharmaceuticals (REGN) - 7,402 Pure Storage (PSTG) - 136,940 Novartis (NVS) - 53,188 Cellectis (CLLS) -

BABA

2 minute read

Movers

Understanding Regeneron Pharmaceuticals’s Unusual Options Activity

By Benzinga Insights

Today, 2:53 PM

On Friday, shares of Regeneron Pharmaceuticals (NASDAQ:REGN) saw unusual options activity. After the option alert, the stock price moved up to $603.32.

REGN

1 minute read

Ocular Therapeutix, Regeneron Cull Aflibercept Agreement For Retinal Diseases

By Vandana Singh

Today, 2:53 PM

Ocular Therapeutix Inc (NASDAQ:OCUL) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN) have terminated the option and license agreement collaboration. The termination is effective immediately.…

OCUL

1 minute read

Oppenheimer Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to $825

By Benzinga Newsdesk

Today, 2:53 PM

Oppenheimer analyst Hartaj Singh maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Outperform and raises the price target from $725 to $825.

REGN

1 minute read

Barclays Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $705

By Benzinga Newsdesk

Today, 2:53 PM

Barclays analyst Carter Gould maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and raises the price target from $675 to $705.

REGN

1 minute read

SVB Leerink Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to $725

By Benzinga Newsdesk

Today, 2:53 PM

SVB Leerink analyst Geoffrey Porges maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Outperform and raises the price target from $641 to $725.

REGN

2 minute read

Ocular Therapeutix Announces Termination Of Collaboration With Regeneron To Develop A Sustained-Release Formulation Of Aflibercept For The Treatment Of Wet AMD And Other Serious Retinal Diseases

By Bill Haddad

Today, 2:53 PM

Ocular plans to Continue its Efforts to Explore Innovative Anti-VEGF Agents BEDFORD, Mass.--(BUSINESS WIRE)-- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development,

OCUL